FCF $698m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+4.3%TTM YoYC+
Revenue +4.3% — steady but below market-beating range
D/E0.02A-
D/E 0.02 — less debt than most Healthcare peers (≈25th pctile)
P/S7.6xC+
P/S 7.6x — above the Healthcare median (≈75th pctile)
PEG0.05A
PEG 0.05 — exceptional; paying well under fair value for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 54.9
Quality0.36
Growth0.61
Value0.87
Why this score
Diluting shareholders
Foreign reporter (EUR)
Entry · Margin of safety
52-week rangeNear 52-week low
25% off the 12-month high
vs DCF fair value73% aboveest. fair value ~$54
What the price assumes: free cash flow compounding at ~24% a year for the next decade — vs the ~16% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability10% · C+gross profit ÷ total assets (Novy-Marx)
ROIC-5.7% · Freturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Biotechnology · market cap $23.3b. Down 25% from 52-week high of $124.00 — deep drawdown territory. PEG 0.05 — paying under fair value for the growth rate. 20 sell-side analysts rate this a Buy with a mean 1-yr target of $122.40 (implying +32% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -39.6%) — path to GAAP profitability is the core thesis risk. ROE -6% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
Horizon
1-3 yr $122.40 (20-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $214.07 — requires the platform / technology to reach commercial scale. 10 yr $382.58 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
BNTX vs the Top Picks average
Pillar
BNTX
Book avg
Diff
Quality
0.36
0.83
-0.47
Growth
0.61
0.92
-0.31
Value
0.87
0.75
+0.12
Averaged across the 30 names in today's Top Picks (mean score 82.4). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · BNTX
Trend
-0.2 over 37 daily scores
From 55.1 (Jun 22) → 54.9 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · BNTX
$
%
%
Shares to buy
21
Position size
$1,949
3.9% of portfolio
Stop price
$69.60
25% below $92.80
$ at risk if stopped
$487.20
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
BioNTech SE (BNTX): score, valuation & FAQ
BioNTech SE (BNTX) is a Biotechnology company that scores 54.9 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (A) and D/E (A-). On valuation, BNTX sits about 73% above our discounted-cash-flow fair value — the current price implies roughly 24% annual free-cash-flow growth over the next decade.
Is BNTX a good stock to buy?
Bull Rankings scores BNTX 54.9 out of 100 on its quality-growth model, which is a middling reading. That is driven by PEG (A) and D/E (A-). A score is a quantitative screen of BioNTech SE's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does BNTX score 54.9 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). BNTX earns its highest marks on PEG (A) and D/E (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is BNTX overvalued or undervalued?
Based on $92.80, BNTX sits about 73% above our discounted-cash-flow fair value — the current price implies roughly 24% annual free-cash-flow growth over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in BNTX?
Currently unprofitable (margin -39.6%) — path to GAAP profitability is the core thesis risk. ROE -6% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.